Margarita Hospedales
Dados Biográficos
| ID | 6778099 |
|---|---|
| NOME | Margarita Hospedales |
| PRENOMES | Margarita |
| SOBRENOME | Hospedales |
| ASSINATURA | HOSPEDALES M |
| AFILIAÇÕES | Generalitat de Catalunya |
| ORCID | 0000-0001-6367-4502 |
| VERIFICADO | Sim |
| TOTAL DE OBRAS | 2 |
| TOTAL DE CITAÇÕES | 0 |
| TOTAL COMO AUTOR | 2 |
| TOTAL COMO EDITOR | 0 |
| PRIMEIRO ANO DE PUBLICAÇÃO | 2016 |
| ANO MAIS RECENTE DE PUBLICAÇÃO | 2017 |
| ÍNDICE H | 0 |
M-Resist, a modular intervention programme addressed to patients with treatment-resistant schizoprenia
In European Union, between 0.2 and 2.6% of the population suffer from psychotic disorders (Wittchen et al., 2011). The largest group is patients with schizophrenia, and around 40% can be considered resistant to pharmacological treatment (Essock et al., 1996; Kennedy et al., 2014). Standard intervention in patients with treatment-resistant schizophrenia (TRS) is difficult due to the persistence of positive symptoms, extensive periods of hospitaliz…
An innovative and integrative m-Health solution for treatment resistant schizophrenia patients
In the European Union, it is estimated that around 5 million people (0.2-2.6%) suffer from psychotic disorders. Between 30-50% can be considered resistant to treatment, and 10-20% ultra-resistant (Juarez-Reyes et al., 1995; Essock et al., 1996). The standard intervention in patients with resistant schizophrenia is complex, mainly for the presence of persistent positive symptomatology, extensive periods of hospital care and greater risk of multi-m…
Sem obras proeminentes nesta página.
An innovative and integrative m-Health solution for treatment resistant schizophrenia patients
In the European Union, it is estimated that around 5 million people (0.2-2.6%) suffer from psychotic disorders. Between 30-50% can be considered resistant to treatment, and 10-20% ultra-resistant (Juarez-Reyes et al., 1995; Essock et al., 1996). The standard intervention in patients with resistant schizophrenia is complex, mainly for the presence of persistent positive symptomatology, extensive periods of hospital care and greater risk of multi-m…
M-Resist, a modular intervention programme addressed to patients with treatment-resistant schizoprenia
In European Union, between 0.2 and 2.6% of the population suffer from psychotic disorders (Wittchen et al., 2011). The largest group is patients with schizophrenia, and around 40% can be considered resistant to pharmacological treatment (Essock et al., 1996; Kennedy et al., 2014). Standard intervention in patients with treatment-resistant schizophrenia (TRS) is difficult due to the persistence of positive symptoms, extensive periods of hospitaliz…
Digital Mental Health Interventions (2 obras) · Intervention (counseling (2 obras) · Medicine (2 obras) · Psychiatry (2 obras) · Psychosocial (2 obras) · Schizophrenia (object-oriented programming (2 obras) · Disease (1 obras) · Environmental health (1 obras) · Family Caregiving in Mental Illness (1 obras) · Health care (1 obras)